AHR and triple-negative breast carcinoma: Regarding the AhR and cell cycle progression, it has also been reported that activation of the AhR by tranilast [52], an antiallergy medication that has demonstrated AhR agonistic activity, resulted in inhibition of mammosphere formation in drug-surviving cancer stem cells in the triple-negative breast cancer cell line MDA-MB-231, as well other oncogenic cell lines (BT474, SUM149 and SUM159).